Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Lilly pens deal with Gateway Labs alumni Amplitude for RNA vaccine platform for infectious disease

Lilly pens deal with Gateway Labs alumni Amplitude for RNA vaccine platform for infectious disease

August 20, 2026Posted inBiotechnology

Eli Lilly has turned to one of its Gateway Labs residents to help the Big Pharma develop trans-amplifying RNA (taRNA) vaccines for infectious diseases.

Post navigation

Previous Post
Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
Next Post
Chai tees up Bristol Myers Squibb AI antibody discovery collab

Recent Posts

  • Single- and bimetal nitrogen-doped carbon catalysts show promising laboratory ORR performance
  • EQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private
  • Proteins Circulating in Blood Linked to Future Risk of Prostate Cancer
  • Molybdenum–titanium nanopillar sensor detects ammonia at 2 ppm
  • Nvidia, UW Institute for Protein Design Unveil Open-Source Protein Design AI Model

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top